Genetic Technologies Limited： Project Shivom Strategic Alliance
　　Genetic Technologies Limited: Project Shivom Strategic Alliance　　March 06, ET|Source:Genetic Technologies Ltd　　MELBOURNE, Australia, March 　06, 2018 　(GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular provider of BREVAGenplus,a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-binding terms sheet with Omix Ventures Private Limited which operates Project Shivom, as further described below. (“Project Shivom”).　　Project Shivom has announced that it is planning to accumulate and create the world’s largest sequenced genetic database. The collaboration with GTG　　Provide a framework for GTG to become a collaborative laboratory as part of a global network of laboratories as envisaged by Project Shivom,　　Enhance GTG’s experience in the development of predictive cancer tests through access to a large population of data and new markets,　　Potentially form the basis of a new data monitoring and real time risk assessment service,　　Allow GTG, through access to this significant pool of data to modify its risk assessment kits for additional ethnicities as well as the potential to develop new products based on opportunity and areas of need,　　Provide Project Shivom with access to GTG’s CLIA accredited laboratory situated in Victoria. It is expected that this relationship could result in GTG increasing its operations in terms
comprehensively improving its database and generating increased revenues on a pay per use basis,　　Provide an opportunity for GTG to offer genetic counselling and become part of the global genetic counselling network as envisaged by Project Shivom.　　Project Shivomis in the process of establishing a Precision Medicine “ecosystem” – a decentralised blockchain where people can get their genome sequenced and stored. Project Shivom, subject to patient take-up / market penetration, plans to collect significant volumes of genomic data in order to create a platform to provide ancestry data, personal health insight and genomic data for research, and it is seeking to collaborate with partner organisations such as GTG across multiple industries to establish a fully integrated, open, shareable, scalable ecosystem.　　Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The Board is excited about the opportunity to collaborate with Project Shivom on its unique blockchain platform. Where the formal terms are agreed with Project Shivom,access to such a large database of genomic data would allow GTG to utilize its SNP based risk assessment technologies and Australian CLIA accredited laboratory tofacilitate the potential further development of other predictive cancer tests, enabling GTG to offer a comprehensive risk assessment portfolio."　　FOR FURTHER INFORMATION PLEASE CONTACT　　　Dr Paul KasianJason Wong (USA)Director and Interim CEOBlueprint Life Science GroupGenetic Technologies Limited+1 (415) 375 3340, Ext. 4+ 61 3 About Genetic Technologies Limited　　Genetic Technologies is a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visitwww.brevagenplus.comandwww.phenogensciences.com.　　Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visitwww.gtgcorporate.com　　About Project Shivom　　Project Shivom is powering the next era of genomics through blockchain technology – protecting identity, personalizing healthcare and transforming lives. For the first time ever, a precision medicine ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics, and associated apps and services to drive personalized medicine. We further aim to extend our services to form a global network of laboratories and research centres, as well as genetic counsellors and other relevant services. For further information, please visit:https://shivom.io/　　Safe Harbor Statement　　Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of thePrivate Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.　　Related ArticlesMore articles issued byGenetic Technologies LtdMore articles related to:Company Announcement　　Profile　　Genetic Technologies Ltd　　Subscribe via RSS 　　Subscribe via ATOM　　Javascript　　Fitzroy, 　AUSTRALIA　　Media Files　　Genetic Technologies Ltd 　Logo　　LOGO URL| Copy the link below　　Formats available:　　Original　　Medium　　Small
责任编辑：wq
禁止发表不文明、攻击性、及法律禁止言语
请发表您的意见（游客无法发送评论，请
还可以输入 140 个字符
热门评论网友评论只代表同花顺网友的个人观点，不代表同花顺金融服务网观点。
以下为热门自选股
代码|股票名称
同花顺财经官方微信号
手机同花顺财经
专业炒股利器
同花顺爱基金Shivom会成为人类的救世主吗？_区块链_金色财经
Shivom会成为人类的救世主吗？
虽然收看币胜客的韭菜们都是在瑟瑟发抖的冬天，但是座标墨尔本的Connie可是即将迎来炙热的盛夏呀～说到夏天，阳光沙滩比基尼完全就是必备套组。但为了要能够尽速消除冬天狂吃火锅累积出来的小肉肉，Connie近期真是无所不用其极的想方设法，最后发现原来澳洲药房竟然有一个神器，只需要放在口中十秒，就能够「对症下药」，以你的基因去分析最适合你的饮食及生活习惯。
基因组学对人类最大的福音，就是以基因学的方式进行治疗，或是早期预防。但目前医生尚未普遍将基因疗法应用于日常诊疗的其中一个重要原因，是他们缺少能够迅速洞察数据、确定最佳疗法的可视化工具和分析软件。
对医生来说，精准医疗需要的并不仅仅是基因组数据的堆积，而是让这些数据深刻能发挥作用。易于操作的、并且能实时综合患者信息与基因数据库的平台非常重要。基因组的数据处理是化学反应里最重要的催化剂，因为当医疗机构拥有基因组数据分析能力时，才能让更多的患者受益。
在过往，解决数据共享问题，的确需要多方共同努力。大量的编码人员、化学家，甚至能存储大数据的终端机。但Shivom用技术打破数据壁垒，将成为基因组学和医疗保健的下一个风口。
在互联网和web 2.0以后，区块链一直都是被喻为即将改变人类未来生活的下一代的工业革命。Shivom将生物遗传学结合区块链技术，建立革命性的医学基因学生态系统，成为地球上最大的基因组数据中心。贡献者拥有他们的基因组数据、访问权及分享或出售的机会，也让个性化医疗不再遥不可及。
Shivom为患者和基因组数据提供了首个完整的解决方案。让每个人都能有自己的基因组数据，并且确保基因数据由数据贡献者自己拥有，同时被安全地存储。这个生态系统将提供一个开放的基因数据网络市场，使直接面向消费者的业务更加开放、公平，并惠及所有用户。
随着基因组数据在临床中的普及，科学家和医生更加需要使用自动化和标准化的数据资料库。在过去十年来，基因组数据采集的增长率一直在上升，大约每七个月数据总量就会翻涨一倍。Shivom的最终目标是建立一个全球基因组学顾问网络，并打造远程医疗生态系统。
在Shivom的首页上，朴实无华的字体沉静而有力地记述着堪称伟大的愿景：
一个医疗可以防患于未然的世界；
一个重大疾病可以被征服的世界；
一个全球人口都拥有健康的世界；
一个智能医疗为你我护航的世界。
当基因学与区块链技术携手，逾7000种疑难杂症将得以攻克，包含各类传染病，心脑血管疾病，神经衰退，甚至癌症。Connie觉得，Shivom这个项目称得上是真正意义上的价值投资，本质提升全人类的健康水平，解读基因密码，根治疑难杂症，是多么有意义的一件事。这一次，我们不只为钱投资。
本文来源：
文章作者： 口袋币讯
声明：本文由入驻金色财经的作者撰写，观点仅代表作者本人，绝不代表金色财经赞同其观点或证实其描述。
比特币实时价格 ￥42378.05(数据来源：火币Pro)
京ICP备号Copyright (C) 金色财经 版权所有
您投送的稿件违反了金色财经的投稿协议，现已关闭您的投稿功能，如有异议请发邮件至进行申诉。